Cross-sectional epidemiological study in patients with diagnosis of GERD (Gastroesophageal Reflux Disease) and with current treatment or with a history of recent treatment with some PPI (Proton Pump Inhibitor), in order to evaluate the persistence and / or relapse of symptoms of GERD.
OBJECTIVE: To carry out an evaluation about the persistence and / or relapse of symptoms in Colombian patients with diagnosis of GERD. MATERIALS AND METHODS: A multicentric cross-sectional epidemiological study will be carried out in Colombian patients with diagnosis of GERD and with current treatment or with a history of recent treatment with some PPI (Proton Pump Inhibitor). The persistence and / or relapse of symptoms will be evaluated as the main variable. The secondary variables to be evaluated include: Demographical analysis, treatment (s) used by patients, adverse events associated with the treatments, comorbidities and risk factors. The analysis will be carried out from two perspectives: A first descriptive approach and a second analytical approach, with a level of significance of 5%.
Study Type
OBSERVATIONAL
Enrollment
1,500
None. It is an observational study
Scandinavia Pharma
Bogotá, Colombia
RECRUITINGSymptoms of GERD (Gastroesophageal Reflux Disease)
Proportion of patients with persistence and / or relapse of symptoms of GERD.
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years
Demographic analysis
Characterization of patients
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years
Kind of IBP taked by the patient and the way to consume it.
A descriptive analysis of the type of IBP types taken by patients and how to take them
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years
Adverse Events related with the treatments
Evaluation of Adverse events associated with the treatment (s)
Time frame: It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.